Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union
BioDrugs · 2026
DOI: 10.1007/s40259-026-00786-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioDrugs, 2026. Verfasst von Rakesh Aithal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Biologics, Science Division, United States Pharmacopeia India Pvt Ltd, Hyderabad, Telangana, India. rakesh.aithal@USP.org. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Antibodies, Monoclonal, Drug Approval. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Monoclonal antibodies (mAbs) have revolutionized therapeutic treatments by their ability to target specific antigens, leading to enhanced clinical outcomes over other drugs. They are one of the largest modalities within the growing biotherapeutics space and are indicated for a range of diseases. Though transformative, mAbs are still not readily accessible to many patients globally because of their high costs. An increasing number of mAbs are losing patent exclusivity, which has opened the door for the development of biosimilars that could drive down costs and ensure increased access to these life-saving drugs. Regulators approve biosimilars after conducting a rigorous evaluation similar to any other biologic medicine to ensure the safety, quality, and efficacy of these products. To establish biosimilarity, extensive comparative analytical and clinical studies of the biosimilar product with the approved reference product is a regulatory expectation. Growing acceptance from regulators to potentially waive clinical efficacy studies when robust evidence for similarity with reference product is established from analytical, functional, and pharmacokinetic/pharmacodynamic studies will have a major impact on reducing the time and cost of developing biosimilars. Comparative analytical assessment includes side-by-side analysis of the biosimilar with the reference product to demonstrate similarity regarding their physicochemical and functional characteristics. This is usually achieved by identifying product quality attributes (PQAs) that could impact clinical safety and efficacy and applying orthogonal analytical methods to characterize these attributes to identify any differences between the products. This review identifies the common PQAs studied for approved mAb biosimilars in the United States and the European Union through to the end of 2024. We have also compiled the data for the analytical methods used to characterize these attributes and identified a subset of methods universally used among biosimilar applicants. Finally, a brief overview of the risk-based analysis of attributes is summarized from the regulatory submissions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Biologics, Science Division, United States Pharmacopeia India Pvt Ltd, Hyderabad, Telangana, India. rakesh.aithal@USP.org.
- Biopharmaceutical Development, AstraZeneca, Gaithersburg, MD, USA.
- Global Biologics, Science Division, United States Pharmacopeia, Rockville, MD, USA.
- Global Biologics, Science Division, United States Pharmacopeia, Rockville, MD, USA. niomi.peckham@USP.org.
Zitieren
APA
Aithal, R., Majedi, O. M., McCarthy, D., Atouf, F., & Peckham, N. (2026). Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union. BioDrugs. https://doi.org/10.1007/s40259-026-00786-w
Vancouver
Aithal R, Majedi OM, McCarthy D, Atouf F, Peckham N. Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union. BioDrugs. 2026. doi:10.1007/s40259-026-00786-w
BibTeX
@article{Aithal2026,
author = {Aithal, Rakesh and Majedi, Olivia M and McCarthy, Diane and Atouf, Fouad and Peckham, Niomi},
title = {Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union},
journal = {BioDrugs},
year = {2026},
doi = {10.1007/s40259-026-00786-w}
}
EUVIMED